

## Quarterly Activities & Cashflow Report

Quarter ending 30 June 2024

BRISBANE, AUSTRALIA, 31 July 2024: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary applied materials technology, is pleased to release its Appendix 4C – Quarterly Cashflow report and Activities Update for the quarter ended 30 June 2024 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

### Highlights

#### Clean Energy Technologies

- Accelerating clean energy commercial activities following completion of \$6.8m capital raise
- Key anode performance hurdle achieved using Anteo X<sup>TM</sup> – 1,000+ charge & discharge cycles with 70% energy retention - supporting data presented at AABC Europe 2024 industry meeting
- ‘EV1’ moves to evaluate Anteo X<sup>TM</sup> in their prototyping process for next generation batteries
- Scoping a development proposal with EV2 for the development of their next generation high silicon containing anodes
- Separator materials supplier validating Anteo X<sup>TM</sup> capability to mitigate fires in Li-ion batteries
- First production-scale run of Anteo X<sup>TM</sup> completed at the new Brisbane production facility - Performance meeting expectations with further validation runs ongoing
- European based Vice President, International Sales to drive global CET activities –contract being finalised

#### Life Sciences

- Serum Institute of India (SII) enters into Purchase Agreement for USD1.8m of AnteoBind over 5 years subsequent to end of quarter
- Launch of new product AnteoBind NXT<sup>TM</sup>
- Initial biosecurity work completed for Australian State Government department

#### Corporate

- Share Purchase Plan (SPP) offer to existing shareholders and Placement to sophisticated investors completed, raising \$6.8m proceeds in the quarter.
- Cash balance of \$5 million as at 30 June 2024 with no debt – additional \$3.0m R&D funding estimated to be received this year.

David Radford, CEO and Managing Director commented:

*“It is my privilege to thank existing and new shareholders for their participation in the recent capital raise which was very well supported. Following the completion of this raise during the quarter there is considerable operational momentum building through both the Clean Energy and Life Sciences divisions of the business. This saw us execute our largest ever commercial agreement in July 2024 with*

*the Serum Institute of India, with a new USD1.8 million take or pay purchase agreement, following over 18 months of engagement to improve their vaccine quality processes. With a typical 20-year life of a new vaccine, and other vaccines planned, we see this as a highly prospective profitable strategic partnership for AnteoTech.*

*The international battery market continues to evolve and change. Pleasingly, the battery development initiatives constant push for higher performance and cost-effective batteries provides significant opportunities: specifically, the high silicon anodes that the Company is developing which have application for both hybrid and full EV technologies. Growth in the silicon anode segment in 2025 has been estimated by Benchmark Mineral Intelligence to be greater than 100% with a cumulative annual growth rate of ~30% through to 2030. The Company continues to develop a portfolio approach to the market to ensure that there are multiple future revenue streams that include the high silicon anode, Anteo X and the new separator project. In order to drive these opportunities, the Company has identified a new Vice President, International Sales who will shortly join our team. Based in Europe, one of their key focuses will be to cement our key relationships with the two leading electric vehicle manufacturers, EV1 and EV2, and turn those into long-term commercial arrangements.*

*This quarter we continued to build our reputation for battery performance improvement at two major international conferences, where we presented technical data that an anode containing Anteo X had exceeded the 1,000 charge and discharge mark. With a host of ongoing development programmes in electric vehicles and consumer electronics, we remain focused on driving short-term revenues from existing and future partners. As part of the prioritisation of our resources, we have also agreed to terminate our engagement with Trinseo, which, despite us demonstrating that Anteo X exceeded their project criteria, have not pursued our planned collaboration, following their internal restructuring to meet market challenges in the chemical sector.”*

## Clean Energy Technologies – next generation battery technology

### **EV1 confirms Anteo X provides major performance benefits – moves to prototyping**

Good progress was made during the Quarter with the leading European car manufacturer ‘EV1’ whose ongoing evaluations confirmed that use of Anteo X in their anodes, both reduces their input costs and improves the performance of their proprietary anode. EV1 has indicated that the prototyping process incorporating Anteo X is commencing as part of the evaluation process that is typical for all EV manufacturers. In parallel, EV1 has advised that they will be accelerating their assessment of higher silicon anodes (>20%) and they expect to purchase some proprietary high silicon anodes from AnteoTech in 1H FY25. This increased exposure to EV1’s development provides potential opportunities for both Anteo X sales and licencing revenues for the high silicon anodes (including development contracts).

### **Increased engagement with EV2 and five other electric vehicle manufacturers**

This Quarter, AnteoTech management participated in two key battery industry events, being the 14<sup>th</sup> Advanced Automotive Battery Conference or AABC Europe 2024, in Strasbourg France and then The Battery Show in Stuttgart Germany. These events have led to multiple engagements with current and new potential customers.

In connection with this, AnteoTech management are scoping a specific proposal with a second, leading European car manufacturer ‘EV2’, to develop a proprietary ultra-high silicon anode. The development program, once finalised, is targeted for their next generation of batteries which will power an extensive range of electric vehicles. This development work is expected to commence upon EV2’s

completion of the design specifications for their next generation batteries. AnteoTech is working closely with the design team as these specifications are developed.

Importantly, in comparison to the work AnteoTech is undertaking with EV1, the work with EV2 is focused on the evaluation of a prototype anode and does not require the preliminary chemistry testing and evaluations prior to the design freeze for the chemistry. This approach may provide an accelerated pathway to a design freeze for the anode, scale up and commercial agreement.

There are other discussions and proposals being progressed with a further five electric vehicle manufacturers, all from Europe and with significant future potential. The technical data released at the AABC Europe 2024 event has provided a key catalyst for interest and awareness of AnteoTech. As these are in the early stages, the primary focus for AnteoTech remains successfully completing the respective development phases with EV1 and EV2 to achieve commercial outcomes and sales.

### **Leadership team expanded - European Vice President, International Sales**

As previously advised, the Company is in the process of appointing a VP- International Sales, based in Europe, to develop closer relationships with existing and prospective customers. Contract terms are currently being finalised.

### **Work in consumer electronics and safer lithium-ion batteries**

In parallel with the ongoing development work with EVs, AnteoTech has been collaborating with a number of battery companies from gigafactories through to bespoke battery manufacturers who are evaluating Anteo X for use in consumer electronics. The Company now has opportunities under evaluation across a diverse range of battery applications from EVs through to medical devices and consumer electronics. These companies are undertaking evaluations of the technologies using samples of Anteo X to increase energy density and improve battery performance.

As a result of the increased marketing initiatives at trade shows, AnteoTech has been approached by a battery component company who have agreed to the in-principal terms and scope of a Materials Transfer Agreement to assess Anteo X with their products with an objective to mitigate the risk of thermal runaway (lithium-ion battery fire). Confirming this benefit would represent a significant step forward in the development of safer battery technologies, with the removal of one of the risks associated with battery fires. Initial results from this assessment are expected in late 2024.

### **Commission of Anteo X Pilot Production Facility Underway**

Following the completion of the construction of the Anteo X production facility in the previous Quarter, the first production-scale batch run of Anteo X was completed. Assessment of this first batch has confirmed that the product is scalable and meeting expected quality standards. Further validation runs are currently underway prior to final release of product.

These initial batches of Anteo X will be used to facilitate external validations which are currently underway as a form of internal development work. The modular design of the production facility allows for ease of expansion and plans for scaling the process are well advanced and will be implemented as initial development work is completed and further commercial demand builds.

### **AnteoTech and Trinseo mutually agree to terminate MOU**

Since execution of a Memorandum of Understanding with Trinseo on 22 February 2023, both parties have been testing Anteo X with Trinseo's VOLTABOND™ binder technology to deliver performance improvements to existing and future customers. In the middle of FY2024, Trinseo confirmed that the agreed performance hurdles had been achieved and the parties had agreed to negotiate a commercial

agreement in good faith, by early in Q4 FY2024. During this period, Trinseo has undergone several rounds of restructuring and cost cutting in their organisation with changes of management involved in the AnteoTech project. Accordingly, AnteoTech and Trinseo, mutually agreed to terminate the development work and the MOU during the past quarter. There are no ongoing financial or legal obligations between the parties.

## Life sciences – New Product and Partnership Discussions

### **Serum Institute of India – Five-year USD1.8m take or pay Purchase Agreement**

The Life sciences team has refocused under the leadership of Ms. Lian. Following the end of the June Quarter, AnteoTech entered into a purchase agreement with the Serum Institute of India (SII), the world's largest vaccine manufacturer, for USD1.8m of AnteoBind over the next 5 years. The purchase agreement stipulates a USD370,000 annual minimum take or pay order, for each of the next five years. The first purchase order for US\$185,000 has been received and will ship in August upon payment prior to the shipment of product.

While SII has been a long-term customer of AnteoTech, in the last 18 months greater collaboration between AnteoTech and SII has identified that AnteoBind offers a more accurate and cost-effective solution in the vaccine development and quality assurance process. This new Purchase Agreement is of high strategic importance to SII, because, upon regulatory approval of their new vaccines, AnteoBind will form part of the core vaccine manufacturing process, which means any future process change requires a new regulatory filing. The purchase of AnteoBind is expected to apply for the life of the vaccine, which in most cases is up to 20 years. Additionally, the agreement and ongoing collaboration offers AnteoTech an opportunity to work together with SII to expand the usage of AnteoBind within SII as they develop new vaccines.

### **Launch of new product AnteoBind NXT**

AnteoBind NXT was developed to provide a cost-effective alternative to currently available particle activation technologies such as EDC. The product was launched through a targeted marketing campaign after extensive evaluations internationally, with initial results confirming the suitability and performance of this product for use in diagnostic tests. Sales revenues are expected to build in FY2025.

### **Biosecurity**

Historically there has been interest from biosecurity organisations to use AnteoBind for improved testing. During the Quarter, an initial, paid development project was undertaken with an Australian State Government department to assess AnteoBind's ability in a simple test to identify parasites in fisheries. This work was successfully completed, and further development projects are being explored that may result in a range of tests with regard to fisheries management internationally.

## Corporate & Financials

### **Capital Raising completed – funding commercial initiatives**

In April 2024, AnteoTech completed at \$5.4m placement and launched a \$1.0m Share Purchase Plan (SPP) to raise a total of \$6.4m. The SPP, which closed in May, closed oversubscribed raising \$1.4m to bring total capital raised to \$6.8m. An attaching listed option was issued for every two ordinary shares acquired under the placement and SPP, at an exercise price of 3.5 cents and an expiry date of 31 May

2026. For every attaching option exercised within 12 months of issue, an additional unquoted bonus option will be issued at an exercise price of 5 cents and an expiry date of 30 April 2027.

The capital raise to fund its clean energy market launch activities and associated scale up infrastructure, was supported by a number of existing shareholders and also included new institutional and family office investors.

The attaching options issued under the capital raise commenced trading on the ASX on 3 June 2024, under the code ADOO.

### Cash and Expenditure

AnteoTech had \$5.0m cash on hand as at 30 June 2024 with no debt.

This Quarter, cash receipts from customers totalled \$20,000. The net cash outflows from operating activities were \$2.4m (down from \$2.70m in the March 2024 quarter) as summarised below - refer Appendix 4 C Quarterly Cash Flow Report

	\$ '000
<strong>Operating Expenses</strong>	
Research and Development	142
Staff, Admin and Corporate	1,974
Other	278
<strong>Investment Expenses</strong>	
Plant & equipment	296
Intellectual Property	134

During this early commercialisation phase, the Company continues to carefully manage its cashflows whilst also managing its overall expenditures. In parallel, the Company is also pursuing funding from non-dilutive sources, with applications being progressed during the Quarter. In addition, approximately \$3.0m of R&D rebate is expected to be received in the December 2024 quarter.

### ASX Listing Rule 4.7C disclosure

This Quarter, \$197,000 were paid to Related Parties, as reported in Item 6.1 of the ASX Appendix 4C (Quarterly Cash Flow Report), for directors' fees.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

### About AnteoTech Ltd (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

### AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

AnteoTech Ltd

**ABN**

75 070 028 625

**Quarter ended ("current quarter")**

30 June 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	20	460
1.2 Payments for		
(a) research and development	(142)	(951)
(b) product manufacturing and operating costs	(2)	(28)
(c) advertising and marketing	(121)	(273)
(d) leased assets	(173)	(679)
(e) staff costs	(1,092)	(4,798)
(f) administration and corporate costs	(882)	(4,309)
1.3 Dividends received (see note 3)		
1.4 Interest received	16	55
1.5 Interest and other costs of finance paid	(9)	(43)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	0	3,781
1.8 Other	(9)	15
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(2,394)</b>	<b>(6,770)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(296)	(1,059)
(d) investments		
(e) intellectual property	(134)	(379)
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(430)</b>	<b>(1,438)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	6,796	11,484
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(563)	(969)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>6,233</b>	<b>10,515</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,618	2,720
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,394)	(6,770)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(430)	(1,438)



Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,233	10,515
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	<b>Cash and cash equivalents at end of period</b>	<b>5,025</b>	<b>5,025</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,025	1,618
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>5,025</b>	<b>1,618</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	197
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

<b>7.</b>	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	<b>Total financing facilities</b>		
7.5	<b>Unused financing facilities available at quarter end</b>		
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,394)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,025
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	5,025
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	2.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Not applicable	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Not applicable	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Not applicable	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Andrew Cook  
Company Secretary  
31<sup>st</sup> July, 2024

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.